We stated that given the potentially wide range of bundling arrangements that might exist, based on the information we had about such arrangements, we could not determine at that time whether there is a universal approach for treating bundled price concessions in the manufacturer's ASP calculation that would address all potential structures of bundling arrangements in a manner that would achieve our goal of ensuring the accuracy of the ASP payment methodology and preventing inappropriate financial incentives
Sucrose-based syrups reduce perceived bitterness by 4060%, and cyclodextrin complexation can mask up to 70%, but neither achieves complete sensory elimination
There is no Phase 1 trial, no toxicology dossier, no characterized human dose, and no adverse-event registry
Inconsistent timing undermines protocol effectiveness
Oxidative stress, inflammation and treatment response in major depression
Pathophysiology of non alcoholic fatty liver disease